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ABSTRACT
(ROS), and lipid peroxidation (43). Studies have demonstrated 
increased glutamate release, activation of glutamate recep-
tors and accumulation of calcium result in increased gluta-
mate (3,21).
Statins are a group of drugs that competitively inhibit the 
3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase, the 
first enzyme of the HMG-CoA reductase pathway. This inhi-
bition impedes production of mevalonate, the next molecule 
in the cascade producing cholesterol. This action ultimately 
█    INTRODUCTION
Spinal cord injury (SCI) is a mechanical insult followed by a secondary cascade of biologic events promoting perma-nent tissue damage. Excitotoxicity, oxidative stress and 
inflammatory response are the mediators of secondary injury, 
which is –theoretically– preventable (5,16). In the central ner-
vous system (CNS), ischemic traumatic injury, cell loss and 
neuronal dysfunction, is thought to be the result of glutamate-
mediated excitotoxicity, formation of reactive oxygen species 
AIm: Extent of secondary injury is the determinant of tissue destruction and functional worsening after primary spinal cord injury 
(SCI). Data have accumulated on alleviation of secondary injury in SCI from many studies on the subject. Besides its cholesterol 
lowering effects, statins are known to have anti-inflammatory and anti-oxidant effects which are the main targets of spinal cord 
research. This study aims to evaluate the effects of atorvastatin on experimental spinal cord ischemia-reperfusion injury.   
mATERIAl and mEThODS: Thirty adult male New Zealand rabbits were allocated into control, ischemia-reperfusion (I/R) and 
treatment groups. Treatment group received 5 mg/kg of atorvastatin via lavage for the preceding 14 days. Other groups received 
placebo during the same time period. After two weeks, animals in the I/R and treatment groups underwent abdominal temporary 
aorta occlusion for 30 minutes. Neurological condition of the animals was recorded during the 48 hours of observation. Afterwards, 
animals were sacrificed and levels of malondialdehyde, glutathione and nitric oxide in spinal cord tissue and plasma and the 
histopathological tissue changes were determined.      
RESUlTS: Animals in the treatment groups demonstrated significantly better results than the I/R group regarding biochemical 
markers. Neurological evaluation using the Tarlov scale demonstrated significantly better results at the 48th hour in treatment group. 
Histopathological results were also better in the treatment groups.   
CONClUSION: Results of this study demonstrate the neuroprotective effects of atorvastatin. Atorvastatin has favorable effects 
on biochemical markers of oxidative stress in SCI. Further studies with larger cohorts and different time periods are also needed.        
KEywORDS: Atorvastatin, Ischemia/reperfusion injury, Statin, Spinal cord injury
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reduces cholesterol in the organism. They are used for treat-
ment of dyslipidemias and prevention of cardiovascular dis-
eases (15,45). On last two decades, extensive research has 
focused on these agents, revealing their neuroprotective and 
immunomodulatory effects (15,29,36,45,50). 
Some benefits of statins in primary and secondary ischaemic 
stroke prevention are established. Although the neuropro-
tective effects of statins are partially understood; correcting 
blood flow, reducing coagulation, reducing oxidative dam-
age and immune regulatory effects seem to be the probable 
mechanisms (15,29,36,45,50).
The aim of this study was to investigate the neuroprotective 
effects of a statin class agent –atorvastatin– on an experimen-
tal spinal cord ischemia-reperfusion injury model in rabbits.
█    mATERIAl and mEThODS
The experimental protocol was evaluated and approved by 
the “Gazi University Medical Faculty, Ethics Review Commit-
tee”. This study was performed at the Gazi University Faculty 
of Medicine, Experimental Research Center. Animals were 
handled as per the laboratory animal welfare guidelines.
A cohort of 30 adult male New Zealand rabbits weighing be-
tween 2.5-3 kg was divided into control, ischemia-reperfusion 
(I/R) and treatment groups. Animals were randomized and all 
evaluations were blind to the investigators. 
Animals were kept in standard laboratory settings with free 
access to food and water. Animals in the treatment group re-
ceived 5 mg/kg of pure atorvastatin (Abdi Ibrahim, Istanbul, 
Turkey) via gastric lavage for the preceding 14 days. In the I/R 
group any treatment was given for the same time period I/R 
injury.
Anesthesia was induced by intramuscular administration of 
70 mg/kg ketamine hydrochloride (Ketalar, Pfizer; Istanbul, 
Turkey) and 5 mg/kg xylazine (Rompun, Bayer; Istanbul, Tur-
key) and allowed breath spontaneously. Body temperatures 
were maintained as appropriate with a heating pad. The arte-
rial pressure and heart rate were monitored continually. The 
spinal cord ischemia-reperfusion model, which was described 
by Zivin and De Girolami (18), was used. After animals were 
placed in supine position operation area, shaved and cleaned 
with 10% polyvinylpyrolidone/iodine. The transperitoneal ap-
proach was used to expose the abdominal aorta. 150 U/kg 
heparin infusion for anticoagulation was performed five min-
utes before clamping. The aorta was cross clamped at two 
sites via two aneurysm clips (70 g closing force, Yasargil FE 
721, Aesculap, Germany). Clips were placed under the surgi-
cal microscope 1 cm below the renal arteries and 1 cm above 
the bifurcation.
Thirty minutes later, the clips were removed and the regen-
eration of the blood flow was observed (11). The incision was 
closed in layers.
In the I/R group and the treatment group, the aorta was oc-
cluded for 30 minutes. Only laparotomy was performed in the 
control group. Two hours after the treatment, the animals were 
allowed free access to food and water. Credé’s maneuver was 
performed to animals with neurogenic bladder at least two 
times a day 48 hours after surgical procedure. Animals were 
euthanized with a high dose of pentobarbital (200 mg/kg). 
Forty-eight hours after the surgical procedure, a 10 cc cardiac 
blood sample was obtained for biochemical analysis. Tissue 
samples were harvested from the spinal cord after T12-S1 to-
tal laminectomies. Spinal cord segments between L2 and L5 
were used for biochemical analysis while segments between 
L5 and S1 were used for histopathological analysis. Levels 
of nitric oxide (NO), glutathione (GSH) and Malondialdehyde 
(MDA) were analyzed in spinal cord and plasma. The tissue 
MDA levels initially peaked 4 hours post-injury. By 12 hours, 
the MDA levels returned to baseline. A second increase was 
observed from 24 hours to 5 days (12). 
Histopathological evaluation was described in another study 
previously Briefly, after fixing spinal cord specimens in 10% 
buffered formalin for a period of ten days, paraffin embed-
ding was performed. Five-micrometer-thick sections were cut 
axially using a microtome (RM 2245, Leica) for hematoxylin 
and eosin (H&E) staining. Slides were evaluated under a light 
microscope (DMI 4000 B Leica) by a histologist blinded to the 
groups (31).
Axonal damage, neuronal degeneration and glial cell infil-
tration were analyzed as histopathological changes. Axonal 
damage was graded as G0 (normal), G1 (mild swelling and 
vacuolization in axons), G2 (severe swelling and vacuolization 
in axons). The intensity of degenerated neurons was calcu-
lated in each field. Glial cell infiltration was graded as +1, +2, 
+3 and +4 according to their intensity in each field (31). 
Spinal cord and plasma levels of NO, GSH and MDA were an-
alyzed. After the last postoperative neurological examination 
blood samples were collected through a cardiac puncture. 
All of the rabbit spinal cord and serum samples in each group 
were used for biochemical analysis. Whole spinal cord tissues 
were washed 2 times with cold saline. It was placed in glass 
bottles, labeled and stored until worked at the deep freeze. In 
blood and tissues NO, GSH and MDA levels were measured 
(2,9,33,37).
Measurement of Serum MDA: 500 ml of serum into one mil-
liliter of thiobarbituric acid/ trichloroacetic acid/hydrochloric-
acid were added. It was vortexed for 30 seconds in microcen-
trifugation tube. After centrifuging the mixture at 10,000 rpm 
for 5 minutes, the supernatant was placed into a glass tube. 
Ten microliters of butylated hydroxytoluene and this mixture 
added in the tube and boiled for 15 minutes. The sample was 
then compared with distilled water and was evaluated Elisa 
reader at 532 nm, and the MDA level was calculated using 
the following formula: Plasma MDA =adsorbance x 19.2 nmol 
MDA/mL plasma (33).
Measurement of Serum GSH: Serum placed into a micro-
centrifuge tube (500 ml) and 1 ml of hydrochloric acid/Na 
dodesyl sulfate/ethylenediamine tetraacetic acid (pH=8.2) 
was centrifuged at 25°C and 12,000 rpm for 5 minutes. Dithio 
Nitrobenzoic acid was maintained at 37°C for 20 minutes (0.3 
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mM) was added to the supernatant. The sample was read at 
405 nm in an enzyme-linked immunosorbent assay reader (2). 
Measurement of Tissue MDA and GSH: Tissue MDA and 
GSH analysis was performed as described by Aykac, Casini 
and Oz previously. Five hundred milligrams of tissue was ho-
mogenized by 5 mL ice-cold 10% trichloroacetic acid solu-
tion; then the homogenate was centrifuged at 3000 rpm for 
10 min and the supernatant MDA level was assayed by thio-
barbituric acid reactive substance formation, after which the 
GSH level was measured by the modified Ellman method. As 
previously reported, 750 µL of supernatant was added to an 
equal volume of 0.67 (w/v) thiobarbituric acid and heated to 
100°C for 15 minutes (2,9,40).
The absorbance of the samples was measured at 533 nm. The 
LP level was expressed in terms of the MDA equivalent using 
an extinction coefficient of 1.56 x 10-5 cm-1 M-1. To determine 
the GSH levels, 0.5 mL of supernatant was added to 2 mL 0.3 
M Na2HPO4· 2H2O solution. Next, 0.2 mL dithiobisnitrobenzoic 
acid solution (0.4 mg/mL in 1% sodium citrate) was added 
and absorbance at 412 nm was measured immediately after 
mixing (2,9,40). 
Measurement of Nitrate Levels: Nitrate levels analysis was 
performed as described by Miranda and Oz previously. The 
nitrate levels were obtained using an enzyme-linked immuno-
sorbent assay reader by vanadium chloride (VCl3)/Griess as-
say. Prior to nitrate determination, tissues were homogenized 
in five volumes of phosphate-buffered saline (pH 7.5) and 
centrifuged at 2000 g for 5 minutes. Then 0.25 mL of 0.3M 
NaOH was added to 0.5 mL supernatant. After incubation for 
5 minutes at room temperature, 0.25 mL of 5% (w/v) ZnSO4 
was added for deproteinization. This mixture was then centri-
fuged at 3000 g for 20 minutes and supernatants were used 
for the assays. Serum samples were deproteinized prior to as-
say. Serum was added to 96% cold ethanol (½ v/v) and then 
vortexed for 5 min.
After incubation for 30 minutes at 4°C, the mixture was centri-
fuged at 14,000 rpm for 5 minutes and the supernatants were 
used for the Griess assay (37,40).
Data collected during the experiment were analyzed with 
SPSS 15 for Windows using t-Test for two independent sam-
ples. The data was expressed as mean ± standard deviation 
and probability (p) value less than 0.05 was accepted as sta-
tistically significant.
█    RESUlTS
Mean tissue MDA level of the control group was measured as 
3.18±0.63 (nmol/gr). Induction of ischemia increased this val-
ue to 5.09±0.84 (nmol/gr) in the I/R group. Mean tissue MDA 
level of the atorvastatin administered treatment group was 
3.20±0.40 (nmol/gr). The difference between the I/R group 
and the treatment group was statistically significant (p=0.001). 
Mean tissue GSH level of the control group was 0.68±0.05 
(nmol/gr) and induction of ischemia decreased this level to 
0.25±0.05 (nmol/gr) in the I/R group. Mean tissue GSH level 
was measured as 0.66±0.10 (nmol/gr) in the treatment group. 
The difference between the I/R group and the treatment group 
was statistically significant (p<0.05).
Mean tissue NO levels of the control, I/R and treatment groups 
were 73.41±12.3, 113.83±10.74 and 85.23±14.95 (nmol/mgr) 
respectively. The difference between the I/R and the treatment 
groups was statistically significant (p<0.05). 
The bar graph in Figure 1 demonstrates mean tissue levels of 
the measured agents.
Mean plasma MDA level of the control group was measured 
as 1.60±0.47 (nmol/ml). Administration of ischemia increased 
this value to 2.46±0.41 (nmol/ml) in the I/R group. Mean 
plasma MDA level of the atorvastatin administered treatment 
group was 1.89±0.44 (nmol/ml). The difference between the 
I/R group and the treatment group was statistically significant 
(p=0.015). 
Mean plasma GSH level of the control group was 352.68±54.13 
(nmol/ml) and induction of ischemia decreased this level to 
233.15±29.66 (nmol/ml) in the I/R group.
Mean plasma GSH level was measured as 331.10±61.06 
(nmol/ml) in the treatment group. The difference between the 
I/R group and the treatment group was statistically significant 
(p=0.001).
Mean plasma NO levels of the control, I/R and treatment 
groups were 116.11±20.94, 257.15±38.46 and 67.86±20.44 
(nmol/ml), respectively. The difference between the I/R and the 
treatment groups was statistically significant (p<0.05).
The bar graph in Figure 2 demonstrates the mean plasma lev-
els of the measured agents.
Neurological status of the animals was evaluated at three dif-
ferent time points using Tarlov scale. The bar graph in Figure 3 
Figure 1: Bar graph demonstrating tissue levels of MDA, GSH and 
NO. (*p<0.05 treatment group versus I/R group).
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damaged in this group. Additionally, structural damage in the 
axons and the extent of glial cell infiltration was significant in 
this group. Axonal damage grading of all of the animals was 
Grade 2 and extent of the glial cell infiltration was consisted 
of 3+ and 4+.
On the other hand, observations demonstrated that atorvas-
tatin administration to the treatment group animals have re-
sulted in better histopathological results. 
Nearly 45% of the neurons were destroyed in this group. Most 
of the axons were spared demonstrating Grade 1 degenera-
tion. Extent of the glial cell infiltration was also milder in this 
group. Table II demonstrates the results of histopathological 
evaluation in groups. Figure 4A-D demonstrate sample speci-
mens from the I/R group and the treatment group.
and Table I demonstrates the evaluation results. Comparison 
of the I/R and treatment groups regarding their Tarlov scale 
results at the 6th and the 24th hours did not reveal any signifi-
cant results (p=0.098 and p=0.153, respectively). On the other 
hand, evaluations performed at the 48th hour demonstrated a 
significant difference between the I/R and treatment groups in 
favor of the treatment group. 
The mean Tarlov score of the treatment group at the 48th hour 
was significantly higher than that of the I/R group (p=0.033).
All of the animals in the control group demonstrated nor-
mal histological structure. Neurons at the anterior horn of 
the spinal cord segments from the animals in the I/R group 
were significantly destroyed. Nearly 84% of the neurons were 
Figure 2: Bar graph demonstrating plasma levels of MDA, GSH 
and NO. (*p<0.05 treatment group versus I/R group).
Table I: The Distribution of the Total Number of Groups of Rabbits according to the Tarlov Score
Control I/R Treatment
Tarlov Score 6h 24h 48h 6h 24h 48h 6h 24h 48h
0 6 4 5 3 2 2
1 3 4 4 3 3 2
2 1 2 1 2 4 4
3 2 1 2
4
5 10 10 10
mean 5 5 5 0.5 0.8 0.6 1.3 1.4 1.6
I/R: Ischemia and reperfusion, h: Hour.
Figure 3: Bar graph demonstrating Tarlov scores of animals at 6th, 
24th and 48th hour. (*p<0.05 treatment group versus I/R group; Ω 
p>0.05 treatment versus I/R group). 
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Figure 4: Photomicrograph demonstrating histopathological evaluation of injured neural tissues from the I/R group and the treatment 
group. A) A specimen from the I/R group. Motor neurons have lost their multipolarity with eosinophilic cytoplasms (thick arrow), 
degenerated white matter (thin arrow) and increased glial cell infiltration (star)(H&E, x10). B) A specimen from the I/R group with white 
mater demonstrating severe axonal degeneration and vacuolization (H&E, x40). C) A specimen from the treatment group demonstrating 
neurons with spared multipolarity and basophilic cytoplasm (thick arrow) with moderate glial cell infiltration (thin arrow)(H&E, x40). 
D) Another slice from the treatment group demonstrating neurons with spared multipolarity and basophilic cytoplasm (thick and thin 
arrows) with moderate glial cell infiltration in white matter (black star) and gray matter (red star) (H&E, x10).
Table II:  Results of Histopathological Evaluation
Control Group I/R Group Treatment Group
Subject Damaged Neurons
Axonal 
Damage
Glial cell 
infiltration
Damaged 
Neurons
Axonal 
Damage
Glial cell 
infiltration
Damaged 
Neurons
Axonal 
Damage
Glial cell 
infiltration
1 0/10 Grade 0 + 8/10 Grade 2 +++ 3/10 Grade 0 +
2 0/10 Grade 0 + 9/10 Grade 2 ++++ 3/10 Grade 0 +
3 0/10 Grade 0 + 9/10 Grade 2 ++++ 5/10 Grade 1 ++
4 0/10 Grade 0 + 7/10 Grade 2 +++ 4/10 Grade 0 +
5 0/10 Grade 0 + 9/10 Grade 2 ++++ 6/10 Grade 1 ++
6 0/10 Grade 0 + 8/10 Grade 2 +++ 6/10 Grade 1 ++
7 0/10 Grade 0 + 9/10 Grade 2 ++++ 7/10 Grade 1 ++
8 0/10 Grade 0 + 8/10 Grade 2 +++ 5/10 Grade 1 ++
9 0/10 Grade 0 + 8/10 Grade 2 +++ 3/10 Grade 0 +
10 0/10 Grade 0 + 9/10 Grade 2 ++++ 3/10 Grade 0 +
I/R: Ischemia and reperfusion.
A B
C D
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Atorvastatin was also studied for spinal cord injury and the 
preventive effects on apoptosis were proven before (15). Neu-
roprotective effects of atorvastatin were well known entity 
(35). The possible effects of atorvastatin on neuronal injury 
are maintaining the integrity of blood brain barrier, lowering 
tumor necrosis factor (TNF)-α, Interleukin (IL)-1β levels and 
suppressing inducible nitric oxide synthase (iNOS) activity 
(13,15,35,42). Besides these, same suppressive activity on 
microglia was demonstrated. These pathways are lowering 
the neuroinflammation. Also favourable effects of atorvastatin 
on neuropathic pain was proven by two studies (13,42).
As far as we are aware, the neuroprotective effect of atorvas-
tatin in spinal cord I/R injury has been evaluated before and 
two studies were published. They conclude that pretreatment 
therapy of atorvastatin was also effective for I/R injury (26,39). 
Anti-inflammatory, antioxidant, and neuroprotective effects 
are discussed as possible mechanisms. 
In our study, we evaluated the effects of atorvastatin pre-
treatment after experimentally induced spinal cord ischemia-
reperfusion injury model on oxidative stress markers by evalu-
ating MDA, GSH and NO levels. Additionally, we evaluated the 
histological and functional outcomes of the treatment. 
High lipid concentration of the nervous system makes it vul-
nerable to the hydroxyl radicals and lipid peroxidation (30). 
Lipid peroxidation aggravates spinal cord hypoperfusion, ede-
ma formation, axonal conduction failure and disturbances of 
energy failure (8,22). 
To evaluate the extent of the peroxidation reaction, MDA, 
which is formed from the breakdown of polyunsaturated fatty 
acids, is used (44). 
An increase in lipid peroxidation in I/R injury of the spinal cord 
and serum has been shown following aortic clamping in the 
recent studies (45,49). Increase in MDA levels following 30 
minutes of reperfusion in patients who undergo coronary ar-
tery surgery have been shown by Belboul et al (6). However, 
Nazli et al. showed increase in MDA levels (39). In our study, 
a significant increase of MDA levels was observed after isch-
emia-reperfusion in the control group. Also, subjects receiving 
atorvastatin had significantly lower tissue and plasma MDA 
levels compared to the I/R group. After an I/R injury, MDA lev-
els increase and lipid peroxidation occurs, thus the presence 
of reperfusion injury is supported. Similar to previous studies, 
our study showed a significant increase in MDA levels after 
I/R injury (39).
Glutathione is one of the principle endogenous anti-oxidant 
molecules and plays an important role in neutralization of free 
radicals and reactive oxygen species The decrease in GSH 
level increases oxidative stres (49). Aydemir et al. have re-
ported a decreased GSH levels at reperfusion by melatonin 
administration. In our study, administration of atorvastatin 
significantly increased the level of GSH both in plasma and 
neural tissue (1).
Nitric oxide is a gas known to induce macrophage cytotox-
icity and has important roles in neural signaling. It has been 
demonstrated that high NO concentrations increases oxida-
█    DISCUSSION
The pathophysiological mechanisms that underlie ischemic 
injury to the spinal cord have not been clearly elucidated. Ex-
tinction of blood supply leads to exhaustion of energy depot 
in the tissue. Energy expenditure triggers ischemic cascades 
and secondary damage ensues. The first event leading to cell 
destruction after ischemia is the depolarization and opening 
of voltage dependent ion channels (i.e. Na+, K+, Ca++) (23). 
This leads to massive release of neurotransmitters including 
glutamate, which causes the opening of glutamate receptor-
operated ion channels.
Ionic disturbances lead to accumulation of intracellular Ca++ 
and initiate damaging cascades. On the other hand reperfu-
sion injury is another serious problem. 
After the increase of blood flow (reperfusion) in the spinal 
cord, oxygen that is needed for production of uric acid is 
supplied from hypoxanthine. Reperfusion of the ischemic tis-
sue leads to influx of excess amounts of oxygen through the 
tissue resulting in formation of free oxygen radicals. These 
oxygen radicals further aggravate tissue damage (10,24,42). 
Glutamate-mediated calcium toxicity induced mitochondrial 
dysfunction and the associated loss of energy supply together 
with formation of free oxygen radicals are important targets of 
spinal cord injury studies (36). These radicals react with the 
cellular lipids and mitochondrial membranes and produce lipid 
peroxides. The lipid peroxidation of membranes causes mem-
brane and cell damage. This process is called “reperfusion 
injury” (46).
Some therapeutic modalities that limit oxidative stress may 
have potential benefit over several neurological diseases. 
Corticosteroids, lazaroids, gangliosides, calcium channel 
blockers, free radical scavengers, magnesium, sodium chan-
nel blockers, cyclosporin A, opioid receptor antagonists, N-
methyl-D-aspartate (NMDA) receptor antagonists, and thyro-
tropin-releasing hormone have been shown to be effective in 
experimental SCI models. In-vivo and in-vitro neuroprotective 
effects of NMDA and non-NMDA receptor antagonists have 
been shown, however their clinical use is being limited by their 
major adverse effects (17).
Another therapeutic agent group that examined for neuro-
nal protection is HMG CoA-reductase inhibitors. Today, the 
anti-inflammatory and neuroprotective efficacy of HMG CoA-
reductase inhibitors in experimental models of diseases such 
as Alzheimer’s, multiple sclerosis and cerebral ischemic injury 
has been proven (7,19,41). The anti-inflammatory effects of 
these statins are the result of their inhibitory effects on adhe-
sion molecules and cell proliferation mediators (particularly T 
cell proliferation and consequent cytokine proliferation). They 
preclude adhesion of inflammatory cells to the endothelial sur-
face. 
Statins also inhibit antigen presentation by antigen present-
ing cells in the peripheral circulation (34,50,51). Additionally, 
statins pose anti-oxidant features by both inhibiting low-den-
sity lipoprotein oxidation and by inhibiting destruction of ni-
tric oxide by free oxygen radicals (28). In their in vitro studies, 
Franzoni et al. have proved antioxidant activities of statins 
(20). 
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tive stress. After spinal cord injury, expression of NO synthase 
–a catalyzer of NO synthesis– increases. Excessive NO has 
cytotoxic effects and induces neuronal apoptosis, neuronal 
degeneration and dysfunction (14,25,32). Our results demon-
strated that the I/R injury significantly increased the NO level 
both in the tissue and the plasma. Administration of atorvas-
tatin to the animals in the treatment group significantly de-
creased these levels. 
Nitric oxide dilates the vessels, induces macrophage cytotox-
icity and plays a role in neural signaling. It is a unique mol-
ecule playing a role in many physiological processes of the 
CNS. Its protective and destructive effects have been shown 
in several neurological disorders. Lower NO concentration has 
been proven to have an important part in physiological pro-
cesses, and higher levels to increase oxidative stress. Induc-
ible NO synthase is expressed in the spinal cord immediately 
after SCI. Synthesis of large NO amounts has cytotoxic effects 
and leads to neuronal dysfunction, secondary neural degen-
eration and neuronal apoptosis (14,25,32,47). Emmez et al. 
performed a study on the effects of alpha-lipoic acid on spinal 
cord reperfusion injury in rabbits and they demonstrated that 
NO levels increased both in the tissue and the plasma after 
the I/R injury. In addition, administration of alpha-lipoic acid 
significantly decreased these levels. Our study showed similar 
results with this study (17).
Similar promising results were also gathered after histopatho-
logical evaluation. The primary injury is followed by post-insult 
inflammation, in which inflammatory cells such as neutrophils, 
macrophages and resident microglia accumulate at the in-
jury site (38). The mediators released by these cells increase 
the tissue damage. Similar to the studies of Hwang et al. and 
Ucak et al. on simvastatin, histopathological evaluation of the 
injured tissues in atorvastatin administered subjects in our 
study demonstrated less injury than the subjects in the I/R 
group (27,48). We concluded that this favorable effect has 
been also reflected, and is the result of better neurological 
outcome scores in the atorvastatin receiving group, as dem-
onstrated in our study (Figure 3).
In current clinical practice, statins are used over a long time 
period to obtain benefit from their anti-lipidemic and cardio-
protective properties. In our study, the significantly better re-
sults with the administration of atorvastatin prior to surgery 
appear to support those data (4). These data corroborate the 
neuroprotective effects of atorvastatin, similar to the literature. 
However, the neurological damage caused by vascular com-
plications is still a major issue and pre-treatment with atorvas-
tatin has promising effects on spinal I/R injury.
█    CONClUSION
We believe that atorvastatin has favorable effects in the spi-
nal cord ischemia reperfusion injury model in rabbits. Further 
experimental studies with larger cohorts and at different time 
points should be performed to project these findings to clini-
cal settings.
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